**Artivion Sees 5.3% Stock Surge Following FDA Approval**
Artivion, Inc. (AORT) experienced a 5.3% increase in its stock price, closing at $35.22 during the recent trading session. This rise comes after the FDA granted premarket approval for the NEXUS Aortic Arch System, developed by its partner Endospan Ltd. Following the approval, Artivion is entitled to acquire Endospan within 90 days.
The company is expected to report quarterly earnings of $0.06 per share, unchanged from the previous year, with projected revenues of $115.95 million—an increase of 17.1% year-over-year. In contrast, Treace Medical Concepts, another player in the medical instruments industry, closed at $1.34, a 6.9% decrease, and is anticipating a loss of $0.27 per share in its upcoming report.
